Petros Pharmaceuticals (PTPI) Competitors $0.12 -0.01 (-5.59%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.13 +0.00 (+2.40%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends PTPI vs. PMCB, CHRO, TLPH, KPRX, KLTO, JAGX, BCLI, PHXM, CSCI, and AIMDShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include PharmaCyte Biotech (PMCB), Chromocell Therapeutics (CHRO), Talphera (TLPH), Kiora Pharmaceuticals (KPRX), Klotho Neurosciences (KLTO), Jaguar Health (JAGX), Brainstorm Cell Therapeutics (BCLI), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. PharmaCyte Biotech Chromocell Therapeutics Talphera Kiora Pharmaceuticals Klotho Neurosciences Jaguar Health Brainstorm Cell Therapeutics PHAXIAM Therapeutics COSCIENS Biopharma Ainos PharmaCyte Biotech (NASDAQ:PMCB) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk. Does the media favor PMCB or PTPI? In the previous week, Petros Pharmaceuticals had 2 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 2 mentions for Petros Pharmaceuticals and 0 mentions for PharmaCyte Biotech. Petros Pharmaceuticals' average media sentiment score of 0.20 beat PharmaCyte Biotech's score of 0.00 indicating that Petros Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment PharmaCyte Biotech Neutral Petros Pharmaceuticals Neutral Does the MarketBeat Community believe in PMCB or PTPI? Petros Pharmaceuticals received 1 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformPharmaCyte BiotechN/AN/APetros PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Do institutionals & insiders believe in PMCB or PTPI? 34.2% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 1.0% of PharmaCyte Biotech shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, PMCB or PTPI? PharmaCyte Biotech has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Is PMCB or PTPI more profitable? PharmaCyte Biotech's return on equity of 0.76% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PharmaCyte BiotechN/A 0.76% 0.45% Petros Pharmaceuticals N/A -78.22%-23.50% Which has stronger valuation and earnings, PMCB or PTPI? PharmaCyte Biotech has higher earnings, but lower revenue than Petros Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharmaCyte BiotechN/AN/A$330K$0.533.32Petros Pharmaceuticals$4.02M0.35-$8.16M-$4.76-0.03 SummaryPharmaCyte Biotech and Petros Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.036.1326.4618.82Price / Sales0.35313.46457.9780.74Price / CashN/A67.8344.0437.47Price / Book0.036.747.634.64Net Income-$8.16M$138.11M$3.18B$245.69M7 Day Performance-57.34%-2.02%-1.82%-2.63%1 Month Performance-60.94%-1.54%0.22%-2.37%1 Year Performance-92.14%-3.14%17.49%13.65% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.6226 of 5 stars$0.13-5.6%N/A-92.1%$1.50M$5.82M0.0020Gap DownPMCBPharmaCyte BiotechN/A$1.63-0.6%N/A-14.6%$11.36MN/A3.084High Trading VolumeCHROChromocell TherapeuticsN/A$1.88+8.7%N/A-64.9%$11.33MN/A0.004TLPHTalphera2.566 of 5 stars$0.65+2.7%$4.33+568.7%-50.8%$11.04M$650,000.00-0.9419KPRXKiora Pharmaceuticals2.2264 of 5 stars$3.62+0.6%$10.00+176.2%-35.3%$10.86M$16M0.0010News CoverageKLTOKlotho NeurosciencesN/A$0.40+8.4%N/AN/A$10.83MN/A0.00N/AGap UpHigh Trading VolumeJAGXJaguar Health0.3048 of 5 stars$0.90+5.3%N/A-78.8%$10.62M$9.76M0.0050Gap UpBCLIBrainstorm Cell Therapeutics4.0752 of 5 stars$1.86+3.3%$30.00+1,512.9%-62.9%$10.60MN/A-0.3940Analyst ForecastNews CoveragePHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049CSCICOSCIENS BiopharmaN/A$2.76-2.5%N/AN/A$10.43M$4.50M-0.2320AIMDAinos0.4072 of 5 stars$0.74+1.2%N/A-23.5%$10.41M$120,000.000.0040Positive NewsGap Up Related Companies and Tools Related Companies PharmaCyte Biotech Competitors Chromocell Therapeutics Competitors Talphera Competitors Kiora Pharmaceuticals Competitors Klotho Neurosciences Competitors Jaguar Health Competitors Brainstorm Cell Therapeutics Competitors PHAXIAM Therapeutics Competitors COSCIENS Biopharma Competitors Ainos Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTPI) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
